CheckMate 274: OS Outcomes for Patients With MIBC

Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai, shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 European Association of Urology Congress. In this study, adjuvant nivolumab demonstrated OS benefit for patients with high-risk MIBC, especially in those with PD-L1-positive disease.

Dr. Galsky comments on how to make sense of these results when compared with AMBASSADOR, which did not reach statistical significance for OS.


Latest News

Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Julian Chavarriaga, MDTesticular, Penile, and Rare Malignancies | April 12, 2024
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Read More
Marco Finati, MDProstate Cancer | April 9, 2024
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Guy Verhovsky, MDUrothelial Carcinoma | April 11, 2024
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Amanda Myers, MDNon-Muscle Invasive Urothelial Carcinoma | April 9, 2024
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.

Video Insights

Clinical discussions with experts in the field

Network Websites